Patient Input for Drug Approval Application (pCODR) - Maribavir

If you have had a hematopoietic stem cell transplant (aka. bone marrow transplant), you can provide feedback that can potentially help make a drug to treat Cytomegalovirus (CMV) infections accessible to patients in Canada.

We invite all patients world-wide who have received a hematopoietic stem cell transplant to share their experience regarding Cytomegalovirus (CMV) infections. CMV is a potentially serious complication that some patients experience following a  hematopoietic stem cell transplantation used to treat their blood cancer.

Over the next few months Maribavir, an orally bioavailable anti-CMV compound, will undergo evaluation through the Canadian Agency for Drugs and Technologies in Health (CADTH) and its Quebec equivalent INESSS, for funding consideration as a new treatment for patients with CMV infections who have inadequate response to corticosteroids or other systemic therapies. By providing your feedback to this survey, you will provide valuable input to a group patient feedback submission that highlights the needs of patients with CMV infections

CADTH is an independent agency that makes funding recommendations to provinces on drugs approved for use in Canada, and INESSS is also an independent agency that makes funding recommendations but for the province of Quebec only.  As always, patient input is particularly important, and your feedback may contribute to increasing availability and access to this therapy for other Canadian patients experiencing CMV infections.

This survey should only take approximately 25 minutes of your time. We ask that the survey be completed by February 28, 2022.

If you have any questions about the survey, please email indrek.koppel@lls.org and indicate ‘Patient Survey’ in the subject line.

Privacy policy: All survey data is being collected by an alliance of the following national, not for profit, charitable, patient-led organizations: Aplastic Anemia & Myelodysplasia Association of Canada, Canadian CML Network, Canadian MPN Network, Canadian MPN Research Foundation, Cell Therapy Transplant Canada, CLL Canada, The Leukemia & Lymphoma Society of Canada, Lymphoma Canada and Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used in the final report to CADTH/INESSS without reference to patient or caregiver name or any other identifying information.

Thank you in advance for your participation and for providing valuable feedback that may help other Canadians impacted by CMV infections!